PUBLISHER: 360iResearch | PRODUCT CODE: 1497796
PUBLISHER: 360iResearch | PRODUCT CODE: 1497796
[187 Pages Report] The Aesthetic Injectables Market size was estimated at USD 11.08 billion in 2023 and expected to reach USD 11.95 billion in 2024, at a CAGR 7.85% to reach USD 18.81 billion by 2030.
Aesthetic injectables are non-surgical cosmetic treatments that involve injecting substances such as botulinum toxin and dermal fillers into the skin to decrease the appearance of wrinkles, enhance facial contours, and restore lost volume. These procedures are designed to provide a youthful appearance without the need for invasive surgery, offering a quicker, less painful alternative with minimal downtime. The heightened societal emphasis on physical appearance and youthfulness fueled by social media and the influence of celebrities is driving the demand for aesthetic injectables. People are more conscious of their looks and seek treatments that help them maintain a youthful appearance. Advancements in minimally invasive techniques have made these procedures safer and more effective, with fewer side effects and shorter recovery times. Rising disposable incomes, which have enabled more people to afford these treatments are boarding the scope of the market. The potential for side effects and complications, which can include bruising and swelling, with the use of aesthetic injectables hampers the market's growth. These risks can deter potential clients. Continuous innovation in injectable formulations and techniques enhances the efficacy and safety of treatments potentially reducing the side effects, and improving results are expected to create opportunities for market growth.
KEY MARKET STATISTICS | |
---|---|
Base Year [2023] | USD 11.08 billion |
Estimated Year [2024] | USD 11.95 billion |
Forecast Year [2030] | USD 18.81 billion |
CAGR (%) | 7.85% |
Regional Insights
The market for aesthetic injectables in the Americas, particularly North America, is robust and continues to grow due to high disposable incomes, a strong emphasis on physical appearance, and widespread acceptance of cosmetic procedures. The presence of a large number of aesthetic practitioners, continuous advancements in injectable technologies, and significant consumer demand drive the market growth in the Americas. South America is representing continuous growth, spurred by increasing awareness and acceptance of aesthetic treatments. In the Asia-Pacific (APAC) region, the aesthetic injectables market is expanding rapidly, fueled by rising disposable incomes, urbanization, and a growing middle class with a strong interest in beauty and personal care. Countries such as South Korea, Japan, and China are at the forefront, with South Korea particularly known for its advanced cosmetic surgery and non-surgical procedure market. The cultural emphasis on youthful appearances and the influence of social media and celebrity culture are significant drivers. Additionally, the relatively lower procedure cost than in Western countries makes these treatments more accessible. The Europe, Middle East, and Africa (EMEA) region presents a diverse market for aesthetic injectables. Countries such as the United Kingdom, Germany, and France lead with high demand for non-surgical cosmetic procedures, driven by high disposable incomes, strong healthcare systems, and widespread societal acceptance. The Middle East shows significant potential, particularly in affluent countries including the UAE and Saudi Arabia, with a strong demand for luxury and beauty services. In Africa, the market is still emerging, with growth primarily in urban centers where economic conditions are improving and awareness of aesthetic procedures is increasing.
Market Insights
The market dynamics represent an ever-changing landscape of the Aesthetic Injectables Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.
FPNV Positioning Matrix
The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Aesthetic Injectables Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).
Market Share Analysis
The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Aesthetic Injectables Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.
Recent Developments
Cynosure and Lutronic Merge to Form Global Leader in Medical Aesthetic Technology
Cynosure and Hahn & Company, the recent acquirer of Lutronic, have announced their definitive agreement to merge Cynosure and Lutronic. Both companies are prominent energy-based medical aesthetic systems providers, and this merger creates a leading global medical aesthetics technology company. The combined entity features a diverse and innovative product portfolio, operational in over 130 countries. [Published On: 2024-01-20]
Galderma Launches FACE by Galderma, a New AR Tool Helps Visualize Injectable Treatment Results
Galderma has introduced FACE by Galderma, an augmented reality (AR) tool designed for aesthetic professionals and patients to visualize injectable treatment results before the procedure begins. This tool provides a simulated real-time "before and after" visual, helping to address patient concerns about the outcomes of injectable treatment. [Published On: 2023-03-22]
FDA Approves SKINVIVE by JUVEDERM, a new U.S. Hyaluronic Acid Injection for Smoother Cheeks
Allergan Aesthetics, an AbbVie company, has announced the U.S. FDA approval of SKINVIVE by JUVEDERM for enhancing skin smoothness in adults over 21. This product is the first and only hyaluronic acid (HA) intradermal microdroplet injection in the U.S., designed to improve skin quality in the cheeks. The injectable contains a small amount of lidocaine and provides hydration and smoothness, with results lasting up to six months and optimal treatment. [Published On: 2023-03-15]
Strategy Analysis & Recommendation
The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Aesthetic Injectables Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.
Key Company Profiles
The report delves into recent significant developments in the Aesthetic Injectables Market, highlighting leading vendors and their innovative profiles. These include Adoderm GmbH, Allergan, Inc. by AbbVie Inc., Anika Therapeutics, Inc., Bio Plus Co., Ltd., Bioxis Pharmaceuticals, Bloomage Biotechnology Corp., Ltd., Bohus Biotech AB, Croma-Pharma GmbH, Cutera, Inc., Cynosure, LLC, Dr. Korman Laboratories Ltd., Galderma SA, Hugel America, Inc., Ipsen Pharma, Laboratoires Vivacy, S.A.S., MedyTox Inc., Merz Pharma GmbH & Co.KGaA, Prollenium Medical Technologies Inc., Revance Therapeutics, Inc., SciVision Biotech Inc., Sinclair Pharma Ltd, Suneva Medical, Inc., Teoxane SA, USWM, LLC, and Zimmer Biomet Holdings, Inc..
Market Segmentation & Coverage
T